Literature DB >> 27736759

Pharmacokinetics of Piperacillin in Critically Ill Australian Indigenous Patients with Severe Sepsis.

Danny Tsai1,2,3, Penelope Stewart2, Rajendra Goud2, Stephen Gourley4, Saliya Hewagama5,6, Sushena Krishnaswamy5,7, Steven C Wallis8, Jeffrey Lipman8,9, Jason A Roberts8,9,10.   

Abstract

There are no available pharmacokinetic data to guide piperacillin dosing in critically ill Australian Indigenous patients despite numerous reported physiological differences. This study aimed to describe the population pharmacokinetics of piperacillin in critically ill Australian Indigenous patients with severe sepsis. A population pharmacokinetic study of Indigenous patients with severe sepsis was conducted in a remote hospital intensive care unit. Plasma samples were collected over two dosing intervals and assayed by validated chromatography. Population pharmacokinetic modeling was conducted using Pmetrics. Nine patients were recruited, and a two-compartment model adequately described the data. The piperacillin clearance (CL), volume of distribution of the central compartment (Vc), and distribution rate constants from the central to the peripheral compartment and from the peripheral to the central compartment were 5.6 ± 3.2 liters/h, 14.5 ± 6.6 liters, 1.5 ± 0.4 h-1, and 1.8 ± 0.9 h-1, respectively, where CL and Vc were found to be described by creatinine clearance (CLCR) and total body weight, respectively. In this patient population, piperacillin demonstrated high interindividual pharmacokinetic variability. CLCR was found to be the most important determinant of piperacillin pharmacokinetics. © Crown copyright 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27736759      PMCID: PMC5119022          DOI: 10.1128/AAC.01657-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Can changes in renal function predict variations in β-lactam concentrations in septic patients?

Authors:  Giuseppe Stefano Casu; Maya Hites; Frederique Jacobs; Frederic Cotton; Fleur Wolff; Marjorie Beumier; Daniel De Backer; Jean-Louis Vincent; Fabio Silvio Taccone
Journal:  Int J Antimicrob Agents       Date:  2013-08-11       Impact factor: 5.283

2.  Population pharmacokinetics of tazobactam/piperacillin in Japanese patients with community-acquired pneumonia.

Authors:  Yukihiro Hamada; Saki Takahashi; Takeshi Hirayama; Keisuke Sunakawa; Masakazu Kuroyama
Journal:  Jpn J Antibiot       Date:  2013-08

3.  First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.

Authors:  Jason A Roberts; Carl M J Kirkpatrick; Michael S Roberts; Andrew J Dalley; Jeffrey Lipman
Journal:  Int J Antimicrob Agents       Date:  2009-12-16       Impact factor: 5.283

4.  Sepsis in the tropical Top End of Australia's Northern Territory: disease burden and impact on Indigenous Australians.

Authors:  Joshua S Davis; Allen C Cheng; Mark McMillan; Alex B Humphrey; Dianne P Stephens; Nicholas M Anstey
Journal:  Med J Aust       Date:  2011-05-16       Impact factor: 7.738

5.  Pharmacokinetics of piperacillin following intravenous administration.

Authors:  M A Evans; P Wilson; T Leung; J D Williams
Journal:  J Antimicrob Chemother       Date:  1978-05       Impact factor: 5.790

6.  Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration.

Authors:  Janattul-Ain Jamal; Darren M Roberts; Andrew A Udy; Mohd-Basri Mat-Nor; Fariz-Safhan Mohamad-Nor; Steven C Wallis; Jeffrey Lipman; Jason A Roberts
Journal:  Int J Antimicrob Agents       Date:  2015-03-28       Impact factor: 5.283

Review 7.  Pharmacokinetic evaluation of piperacillin-tazobactam.

Authors:  Yoshiro Hayashi; Jason A Roberts; David L Paterson; Jeffrey Lipman
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-08       Impact factor: 4.481

8.  Piperacillin: human pharmacokinetics after intravenous and intramuscular administration.

Authors:  T B Tjandramaga; A Mullie; R Verbesselt; P J De Schepper; L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

9.  Critical illness and its impact on the Aboriginal people of the top end of the Northern Territory, Australia.

Authors:  D Stephens
Journal:  Anaesth Intensive Care       Date:  2003-06       Impact factor: 1.669

10.  Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?

Authors:  Andrew A Udy; Jeffrey Lipman; Paul Jarrett; Kerenaftali Klein; Steven C Wallis; Kashyap Patel; Carl M J Kirkpatrick; Peter S Kruger; David L Paterson; Michael S Roberts; Jason A Roberts
Journal:  Crit Care       Date:  2015-01-30       Impact factor: 9.097

View more
  8 in total

1.  Population pharmacokinetics and pharmacodynamics of piperacillin in critically ill patients during the early phase of sepsis.

Authors:  Waroonrat Sukarnjanaset; Sutep Jaruratanasirikul; Thitima Wattanavijitkul
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-04-08       Impact factor: 2.745

Review 2.  Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses.

Authors:  Ibrahim El-Haffaf; Jean-Alexandre Caissy; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2021-04-20       Impact factor: 6.447

3.  Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.

Authors:  Fekade Bruck Sime; Uwe Hahn; Morgyn S Warner; Ing Soo Tiong; Michael S Roberts; Jeffrey Lipman; Sandra L Peake; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

4.  Scaling beta-lactam antimicrobial pharmacokinetics from early life to old age.

Authors:  Dagan O Lonsdale; Emma H Baker; Karin Kipper; Charlotte Barker; Barbara Philips; Andrew Rhodes; Mike Sharland; Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2018-11-26       Impact factor: 4.335

5.  Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation.

Authors:  Cristina Sanches; Geisa C S Alves; Andras Farkas; Samuel Dutra da Silva; Whocely Victor de Castro; Farah Maria Drummond Chequer; Francisco Beraldi-Magalhães; Igor Rafael Dos Santos Magalhães; André de Oliveira Baldoni; Mark D Chatfield; Jeffrey Lipman; Jason A Roberts; Suzanne L Parker
Journal:  Antibiotics (Basel)       Date:  2022-03-24

6.  Comparison of Piperacillin and Tazobactam Pharmacokinetics in Critically Ill Patients with Trauma or with Burn.

Authors:  Daniel J Selig; Kevin S Akers; Kevin K Chung; Adrian T Kress; Jeffrey R Livezey; Elaine D Por; Kaitlin A Pruskowski; Jesse P DeLuca
Journal:  Antibiotics (Basel)       Date:  2022-05-04

7.  Time above the MIC of Piperacillin-Tazobactam as a Predictor of Outcome in Pseudomonas aeruginosa Bacteremia.

Authors:  Elias Tannous; Shelly Lipman; Antonella Tonna; Emma Hector; Ziad Hussein; Michal Stein; Sharon Reisfeld
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

8.  Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children with Normal and Augmented Renal Clearance.

Authors:  Agathe Béranger; Sihem Benaboud; Saïk Urien; Florence Moulin; Emmanuelle Bille; Fabrice Lesage; Yi Zheng; Mathieu Genuini; Inès Gana; Sylvain Renolleau; Déborah Hirt; Jean-Marc Tréluyer; Mehdi Oualha
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.